The Path Toward SuccessfulInnovation in Gene Therapies. Please join us for this free, live Ask the Expert webcast.Just fill out the form below to register.. What does it take to innovate successfully in the field of #genetherapies? Join our webinar this Thursday June 24 to learn from leading investigators in this field as they reveal what it takes to successfully innovate. Find out more and register:
Roland W. Herzog, PhD
Professor of Pediatrics, Riley Children’s Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program Indiana University School of Medicine Dr. Herzog is the Editor-in-Chief of the Molecular Therapy journal from the American Society of Gene and Cell Therapy as well as Professor of Pediatrics, Riley Children’s Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program, Indiana University School of Medicine. Dr. Herzog is a recipient of multiple awards from the American Society of Gene and Cell Therapy, the National Hemophilia Foundation, and the Bayer Hemophilia Program, in addition to others.
Nagendra Venkata Chemuturi, PhD
Scientific Director Research, Global DMPK
Takeda Pharmaceutical Company Nagendra Chemuturi received his bachelor’s degree in Pharmacy, with Distinction and Gold Medals, from Kakatiya University in India. He then worked as a pharmaceutical sales representative before pursuing his PhD at the University of Iowa. He was awarded the American Association of Pharmaceutical Scientists (AAPS) Graduate Symposium Award in 2005 for his dissertation work on the role of nasal drug transporters and metabolism in preferential nose-to-brain uptake of dopamine into the brain. He started his career in the US at Vertex Pharmaceuticals in Massachusetts in 2005. Since then, he has worked at Alcon-Novartis, Seattle Genetics, and Novartis Institutes for BioMedical Research. He is currently with Takeda Pharmaceuticals. His experience lies in the fields of oncology and ophthalmology, having served as DMPK lead on several small and large molecule projects. He is currently working on viral gene therapies includ ing clinical aspects of viral gene therapies. He has given podium presentations at several scientific conferences, is active in AAPS and IQ consortium, co-leading the MABEL working group, and has coauthored several articles and book chapters.
About this event:
Date: June 24, 2021
Time: 11 am EDT | 8 am PDT |
5 pm CEST
Duration: 60 minutes
Gene therapies based on adenoassociated virus (AAV) vectors are emerging as a promising treatment strategy for various diseases, including an inherited form of blindness and spinal muscular atrophy. A major obstacle for the wide use of gene therapy is the potential for immune responses against the vector or its therapeutic gene products.
During this upcoming webinar you’ll have the opportunity to learn from two expert speakers, who are leading investigators in the field of gene therapies, as they reveal what it takes to innovate successfully.
Our distinguished presenter Roland W. Herzog, PhD, Professor of Pediatrics, Riley Children’s Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University School of Medicine, will provide perspective on how gene therapies based on AAV vectors are currently approved, including examples of Phase III clinical trials for coagulation diseases. He will also discuss the role of innate immune signals in the adaptive immune response to AAV gene transfer.
Nagendra Venkata Chemuturi, PhD, Scientific Director Research, Global DMPK at Takeda, will provide a glimpse of the future of gene therapies and what it holds for viral and nonviral gene therapies, with a focus on the critical role of a DMPK scientist and clinical pharmacologist.
Key learning points:
- Learn what is new in the field of viral and non-viral gene therapies
- Discover how to overcome challenges with immune responses against the vector or its therapeutic gene products
- Understand the roles of innate signals in the adaptive immune response to AAV gene transfer
- Learn about opportunities in gene therapy development from a clinical pharmacology perspective.
Who should attend:
- Drug Metabolism and Pharmacokinetics (DMPK) Scientists
- Clinical Pharmacologists
- Gene therapies scientists
- Academia focused in gene therapies
- Biopharma/Biotech focused in gene therapies